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 Abstract 
Endogenous testosterone levels are inversely associated with cardiovascular risk in older men and men 
with cardiovascular disease.  Current data on cardiovascular outcomes of testosterone therapy include 
only observational studies and adverse event monitoring in short term trials that were not designed to 
measure cardiovascular outcomes.  These studies have yielded conflicting results, and some have raised 
concerns that testosterone therapy may increase cardiovascular risk.  A well designed, adequately 
powered, prospective trial will ultimately be required to clarify whether testosterone therapy impacts 
cardiovascular outcomes.  This review describes the findings and limitations of recent studies of 
cardiovascular risk in older men on testosterone therapy and discusses some of the mechanisms 
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Introduction 
Serum testosterone declines gradually as men age.  About 20% of healthy men over age 60 have a total 
testosterone below the normal range determined in healthy young men (1).  The high prevalence of 
lower testosterone in older men and aggressive marketing of new formulations for nonspecific 
symptoms have resulted in a marked increase in testosterone prescribing over the last decade (2-4).   In 
addition, men receiving testosterone are often not being diagnosed or monitored in accordance with 
current guidelines (4).  Testosterone replacement in younger men with diseases of the pituitary-gonadal 
axis is clearly beneficial, but there is little data on the risks or benefits of testosterone in men with age-
related declines in testosterone.  Controversy over the risks of testosterone is thus focused on older 
men without demonstrable pituitary-gonadal disease.   
It has been suggested that testosterone may be associated with cardiovascular (CV) risks based on 
gender differences in atherosclerotic disease and observations of CV events in anabolic steroid abusers 
(5).   More recent studies demonstrating that low testosterone in men is inversely associated with CV 
risk have led to suggestions that testosterone replacement may be beneficial (6).  Safety concerns about 
testosterone came to the forefront after the recent publication of two observational studies suggesting 
associations of testosterone therapy with adverse CV outcomes (7, 8).  These studies were widely 
covered by the media, and cardiologists are likely to see patients with questions about testosterone and 
CV risk.  This article reviews testosterone’s CV effects in adult men, focusing on recent clinical studies.  
While there are concerns that testosterone therapy may increase CV events in older men, limitations of 
existing data leave significant uncertainty.  A well designed, adequately powered, prospective trial of 
testosterone therapy focused on CV outcomes will be required to address these questions. 
Physiology of testosterone actions on the vasculature 
The gonadal axis in adult men is regulated by gonadotropin-releasing hormone (GnRH) from the 
hypothalamus (Figure 1).  GnRH stimulates secretion of luteinizing hormone (LH) and follicle stimulating 
hormone (FSH) from the anterior pituitary (9).  Luteinizing hormone acts on Leydig cells in the testis to 
stimulate testosterone synthesis, while FSH acts on Sertoli cells in the seminiferous tubules to stimulate 
spermatogenesis (9).   Testosterone binds to cytosolic androgen receptors found in most tissues (10).  
The testosterone-androgen receptor complex migrates to the nucleus and where it stimulates 
transcription of numerous genes.  There is also evidence for nongenomic testosterone actions through 
both a membrane-associated form of the classical androgen receptor and a distinct receptor with 
pharmacologic characteristics of a heterotrimeric G protein coupled receptor (11).   
Testosterone is a prohormone.  It is converted to estradiol in many tissues by aromatase, which is 
expressed in many CV cell types.  Circulating estradiol levels in adult men are 10 to 20% of those in 
premenopausal women.  Testosterone is also converted to dihydrotestosterone by 5α-reductase.   
Circulating dihydrotestosterone levels are lower than those of testosterone, but dihydrotestosterone is 
a more potent androgen than testosterone and contributes significantly to testosterone’s effects.  
Testosterone, dihydrotestosterone, and estradiol all exert negative feedback at the hypothalamus and 
pituitary to inhibit LH and FSH release (9).   
Most circulating testosterone is bound to sex-hormone binding globulin (SHBG) or albumin (12).  Only 1-
3% of total testosterone is not bound to plasma proteins.  This unbound, free testosterone is the 
biologically active hormone fraction.   Many clinical conditions alter SHBG concentrations and cause 
corresponding changes in total testosterone.  Obesity, type 2 diabetes, nephrotic syndrome, 
hypothyroidism, and glucocorticoids decrease SHBG; whereas advanced age, cirrhosis and hepatitis, 
hyperthyroidism, some anticonvulsants, estrogens, and HIV infection increase SHBG (12).  Total 
testosterone should not be used to diagnose hypogonadism when a condition that alters SHBG is 
present.  In this situation, it is important to use free rather than total testosterone.   Widely available 
direct free testosterone assays lack precision (12).  A calculated free testosterone is a better marker.   
Serum testosterone also undergoes diurnal variation driven by nocturnal LH surges from the pituitary.  
Levels rise overnight and then decline through the day (12).  A diagnosis of hypogonadism should be 
based on testosterone measurements early in the morning when levels are at their peak. 
Testosterone and dihydrotestosterone exert numerous CV actions through androgen receptors in 
endothelium, vascular smooth muscle, and cardiomyocytes (13).  Estrogen, which is derived from 
testosterone, also has direct CV effects.  In addition, sex steroids modulate inflammation, coagulation, 
and other functions that indirectly affect the vasculature (13,14).   Rapid CV actions of sex steroids, such 
as vasodilation, are mediated by nongenomic pathways (11,15,16).  Longer term actions occur via 
testosterone’s transcriptional pathway (17).  Numerous effects of testosterone on CV physiology have 
been described; and plausible mechanisms for beneficial or adverse clinical outcomes of testosterone 
therapy can be proposed (13,14).  It is thus difficult to predict effects of testosterone on cardiovascular 
events based on its physiologic actions.  Clinical trials are needed to clarify the CV outcomes of 
testosterone therapy in older men.  
Endogenous Testosterone in Older Men 
In healthy men, total testosterone declines about 10% per decade after age 40-50 (18).  Low 
testosterone is also associated with many chronic conditions.  Obesity is strongly associated with low 
testosterone, and levels recover with weight loss (19).  Other conditions associated with low 
testosterone include sleep apnea, type 2 diabetes, hypertension, hyperlipidemia, C-reactive protein and 
other inflammatory markers, chronic kidney disease, chronic obstructive pulmonary disease, HIV/AIDS, 
and chronic opioid use (20).  Levels of LH and FSH do not increase in response to the declining 
testosterone and generally remain in the normal range.  Many, but not all, studies have found low 
testosterone to be associated with CV disease.  A recent meta-analysis of prospective observational 
trials found inverse associations of testosterone with all-cause and CV mortality (21).  Inverse 
associations with incident CV events have also been noted, but only in studies that included men over 70 
years of age (6).  The relative risk for an increase of one standard deviation of testosterone was 0.84 
(95% CI 0.76 to 0.92).   Another meta-analysis confirmed the association of low testosterone with 
mortality, but failed to demonstrate a significant association with incident CV disease (22).  The point 
estimate suggested increased CV disease incidence with lower testosterone, but the 95% CI included no 
effect.  In men with chronic heart failure, testosterone is inversely associated with New York Heart 
Association class, and lower testosterone predicts reduced 3-year survival (23).   
Whether decreased testosterone is a cause of adverse clinical outcomes in patients with CV disease and 
other chronic conditions is unknown.  Younger men with low testosterone due to diseases of the 
pituitary-gonadal axis complain of sexual symptoms, fatigue, mood changes, decreased muscle mass, 
and increased fat mass (12).  These symptoms are common in men with chronic systemic conditions 
even when testosterone is normal.   Conversely, older men with low testosterone are often 
asymptomatic (24).  Testosterone levels in older men thus correlate poorly with symptoms.  There is 
concern that low testosterone in men treated with androgen deprivation for prostate cancer may 
contribute to an increase in CV events and mortality (25).  However, a recent meta-analysis of eight 
prospective, randomized trials of androgen deprivation for nonmetastatic prostate cancer that reported 
CV events by study arm did not find evidence for an increase in CV risk (26).  Admittedly, findings in men 
with castrate testosterone levels due to androgen deprivation may not be generalizable to older men 
with modest reductions in testosterone.   Nevertheless, this result does not support a causal relationship 
between low testosterone and CV events.  Overall, the diversity of chronic conditions associated with 
low testosterone and lack of correlation of testosterone levels with symptoms suggest that low 
testosterone in older men may be more a marker of poor health than a cause of symptoms and clinical 
outcomes.    
Testosterone replacement and cardiovascular events 
It is possible that low endogenous testosterone contributes to CV events and mortality, and that 
testosterone replacement is beneficial.  Alternatively, declines in testosterone with aging and chronic 
disease could be an adaptive response and testosterone replacement may be harmful.  Testosterone 
replacement in men with symptomatic hypogonadism due to diseases of the pituitary-gonadal axis is not 
controversial.  But it is not clear that these benefits translate to men with functional declines in 
testosterone related to chronic diseases or aging.  The only data available are retrospective studies and 
adverse event reporting from short term testosterone trials that were not designed to measure CV 
outcomes.  Major recent studies of testosterone therapy and CV events or mortality are summarized in 
Table 1.   As described below, these studies have yielded conflicting results. 
Two retrospective studies have found testosterone replacement in men with low endogenous 
testosterone to be associated with improved survival.  Shores et al. examined mortality in 1,031 U.S. 
veterans with total testosterone less than 8.7 nmol/L (250 ng/dL), 398 of whom were initiated on 
testosterone therapy in the course of routine care (27).  The average follow up duration was 40.5 
months.  The median time from testosterone measurement to initiation of testosterone treatment was 
3.3 months and the mean duration of treatment was 20.2 months.  Once treatment was initiated, 
subjects were classified as treated for the duration of follow up.  The baseline prevalence of coronary 
disease was 21.9%.  Overall mortality in testosterone treated men was 10.3%, versus 20.7% in untreated 
men.  In a Cox regression model with testosterone as a time varying exposure and adjusted for nine 
covariates, testosterone replacement was associated with a decreased risk of death, hazard ratio 0.61, p 
= 0.008.  If men who stopped treatment were censored 90 days after their last testosterone refill, the 
hazard ratio increased slightly to 0.65, but the p-value was no longer significant.  No information was 
provided on causes of death.  In the other study, Muraleedharan et al. retrospectively reviewed 581 
men with type 2 diabetes who had testosterone measured (28).  Subjects were followed for a mean of 6 
years.  Of the 581 men, 238 had a testosterone level less than 10.4 nmol/L (300 ng/dL), and 64 received 
testosterone therapy for an average of 41.6 months.  In a Cox regression model, the hazard ratio for 
mortality in the treated group versus the group with untreated low testosterone was 0.43, p = 0.004.  
The survival curve for treated patients was similar to that of patients with normal testosterone.  Causes 
of death by treatment group were not reported. 
Two other retrospective studies found testosterone therapy to be associated with increased CV risk.  
Vigen et al. examined a composite outcome of mortality, myocardial infarction, and stroke in male U.S. 
veterans who had coronary angiography and a total testosterone less than 10.4 nmol/L (300 ng/dL) (7).  
Of the 8,709 veterans in the cohort, 1,223 were initiated on testosterone therapy a median of 531 days 
after coronary angiography.   Average follow up was 840 days.  Once initiated on testosterone, patients 
were assumed to continue on therapy.  However, 17.6% of these men filled only one prescription and 
the average duration of therapy for men who filled multiple prescriptions was 376 days.  There were 123 
events in the testosterone group (10.1%) versus 1,587 events in the untreated men (21.2%).  The 
prevalence of coronary disease was 87.4%.  Untreated men were older and had higher rates of 
numerous comorbidities including coronary disease.  In a Cox regression model with testosterone as a 
time-varying exposure and weighted for over 50 other covariates, the hazard ratio for an event on 
testosterone was 1.29, p = 0.02.  This result was not modified by the presence of coronary disease.  
However, the number of subjects without coronary disease was small.  In the other study, Finkle et al. 
examined the risk of nonfatal myocardial infarction (MI) in 55,593 men in a large insurance claims 
database who filled a first testosterone prescription between 2006 and 2010 (8).  The event rate in the 
90 days following testosterone initiation was compared to the rate in the previous year.  The post/pre-
prescription ratio of acute MI incidence was 1.36 (95% CI 1.03-1.81).  Excess post-prescription MI risk 
was only seen in men over 65 or with preexisting heart disease.  An identical analysis was performed on 
167,279 men in the same database who filled a first prescription for a type 5 phosphodiesterase 
inhibitor, a drug class with well-established CV safety.  After odds-of-treatment weighting to adjust the 
distribution of covariates to that in the testosterone cohort, the post/pre-prescription acute MI 
incidence ratio was 1.08 (95% CI 0.93-1.24).  There was no evidence of increased MI risk with 
phosphodiesterase inhibitors in patients over 65 or with preexisting heart disease. 
While each of these studies adjusted for likely confounders, residual confounding is an inherent 
limitation of retrospective studies.  Providers may elect not to offer testosterone to more severely ill 
patients, and such patients may be less inclined to request testosterone replacement.  Another potential 
bias is the common practice of prescribing testosterone for erectile dysfunction, a known predictor of 
CV disease.   In the Shores, Muraleedharan, and Vigen studies, the average duration of testosterone 
treatment was substantially less than the follow up period, implying a high rate of treatment 
discontinuation.  Initial indications for treatment and reasons for discontinuation were not available.  
Only total testosterone levels were reported, presumably because more biologically relevant free 
testosterones were not available.  Testosterone levels were also not consistently measured in the 
morning.  Use of total testosterone and inclusion of testosterone levels measured later in the day likely 
resulted in inclusion of men with normal free testosterone.  The Finkle study attempted to address some 
of these issues by comparing cardiovascular events over the year prior to testosterone therapy to the 90 
day period after therapy was initiated, effectively using each subject as his own control.  However, the 
lack of baseline information on the patients, including testosterone levels and other indications for 
therapy remains a significant limitation.   
The only prospective data on CV risks of testosterone comes from adverse event monitoring in 
randomized trials.  With the exception of polycythemia, discussed below, most trials have not noted 
significant differences in CV events between treatment arms.  This changed in 2010 when the 
Testosterone in Older Men with Mobility Limitations (TOM) trial was terminated early due to excess CV 
events in the testosterone group (29).  The trial had enrolled 209 men at the time it was halted.  The 
TOM trial was following measures of physical performance in men over 65 with limited mobility and 
total testosterone between 3.5 and 12.1 nmol/L (100 to 350 ng/dL) or free testosterone less than 173 
pmol/L (50 pg/mL).  Cardiovascular events occurred in 23 men in the testosterone group and 5 in the 
placebo group.  The odds ratio for CV events was 5.4 (95% CI 2.0-14.9) and changed only slightly after 
adjustment for several risk factors.   The risk of an event was constant over the 24 week intervention 
period.  In a subsequent analysis, the increase in free testosterone on therapy was significantly 
associated with the risk of an event (30).  Participants in the TOM trial were older and had a higher 
prevalence of chronic conditions than most other trials of testosterone therapy.  The testosterone doses 
used were often higher than are typically used for replacement therapy.  Events observed included 
serious events such as myocardial infarction, stroke, congestive heart failure, and atrial fibrillation.  
However they also included less severe events such as peripheral edema, premature ventricular 
contractions, elevated blood pressure, and others.  Testosterone would need to act through multiple 
mechanisms to cause such diverse outcomes.  However, existence of multiple mechanisms is not 
implausible given the pleiotropic CV actions of testosterone discussed above.  Subjects in the treatment 
arm were also referred for evaluation of some noncardiovascular conditions more frequently than 
controls.  This raises the possibility of an ascertainment bias, as some CV events may have been 
discovered incidentally during evaluation of another complaint.   
A 2013 meta-analysis by Xu et al. of 27 testosterone trials that reported CV events by study arm found 
an odds ratio for events on testosterone therapy of 1.54 (95% CI 1.09 to 2.18) (31).  Cardiovascular risk 
on therapy did not depend on baseline testosterone, but did vary with the source of funding.  In 13 
industry-funded studies, testosterone had no effect.  In the 14 studies not funded by industry, the odds 
ratio for an event on therapy was 2.06 (95% CI 1.34 to 3.17).  Men in the industry-sponsored trials were 
younger and had a lower overall event rate, so this difference may reflect lower baseline risk.  One 
limitation of this meta-analysis is variability among the trials in severity of adverse events reported.  
However a similar odds ratio, 1.61 (95% CI 1.01 to 2.56), was seen when the analysis was limited to 
serious events.  The point estimate of the odds ratio for CV death in the testosterone arms was similar at 
1.42, but the 95% CI included no effect.  A 2014 meta-analysis by Corona et al. identified 75 randomized 
trials of testosterone therapy that reported CV events by study arm and examined a composite outcome 
of CV death, acute myocardial infarction, stroke, acute coronary syndromes, and heart failure (32).  
However, this total included many zero-event trials that were excluded from the main analysis, which 
was performed on 26 trials.  The odds ratio for an event on testosterone was 1.01 (95% CI 0.57 to 1.77).  
The Corona study included 5 trials that were excluded by Xu et al., while the Xu study included 6 trials 
that were excluded by Corona et al.  Limitations of both of these meta-analyses include the fact that the 
trials were not stratified by CV risk and did not measure CV events as prespecified outcomes.   Many of 
the trials were limited to subjects with specific conditions such as rheumatoid arthritis, HIV/AIDS, 
cirrhosis, heart failure, COPD, and malnutrition, which may limit the generalizability of the results.  It is 
also important to note that all of the included studies were for short durations, 6 weeks to 36 months.  
There is no good clinical trial data on long term risks of testosterone therapy.  
The mechanisms through which testosterone may modify CV risk are poorly understood.  Physiologic 
testosterone replacement in men with modestly reduced testosterone slightly decreases HDL and has 
little effect on other lipid fractions (33,34).  There is no effect on systolic or diastolic blood pressure (34).  
Testosterone trials in men with type 2 diabetes or metabolic syndrome have consistently demonstrated 
favorable changes in adiposity and insulin resistance, and some have found improvements hemoglobin 
A1c, fasting glucose, and other markers of the metabolic syndrome (19,35).  These observations have 
led to proposals that testosterone-induced improvements in metabolic risk might contribute to 
reductions in cardiovascular disease and other diabetic complications.  However no prospective trial to 
test this hypothesis has been conducted.  There is evidence that testosterone therapy improves exercise 
capacity in men with congestive heart failure (36).  A recent meta-analysis of four randomized trials of 
testosterone therapy in heart failure enrolling a total of 198 subjects found that testosterone treatment 
improved exercise capacity in the 6-minute walk test by 54 meters (95% CI 43 – 65) or the incremental 
shuttle walk test by 47 meters (95% CI 13 – 81).  Peak oxygen consumption was also significantly 
increased.  Treatment durations ranged from 12 weeks to 12 months.  None of the trials showed 
improvements in left ventricular ejection fraction measured by echocardiography, and the authors 
suggested that these improvements occurred via peripheral mechanisms.  Too few clinical events were 
observed to draw conclusions about CV safety.   There is also evidence that testosterone may improve 
myocardial ischemia.  Two randomized trials and one crossover trial examined the effect of testosterone 
treatment for 4 to 52 weeks on ST-segment depression during treadmill exercise testing in a total of 69 
men (37-39).  The three studies observed significantly longer times to 1 mm ST-segment depression, 
ranging from 59 to 109 seconds, in testosterone versus placebo-treated men.  The effect was greater in 
subjects with lower baseline testosterone levels.  The authors speculated that the results reflect a 
vasodilatory effect of testosterone on the coronary vasculature based on similar findings after acute 
intravenous testosterone infusion in other studies.  There was only one serious adverse event in the 
three trials and no conclusions regarding CV safety could be drawn. 
A well-described effect of testosterone that may contribute to CV events is erythrocytosis.  Testosterone 
therapy causes a 3.2% absolute increase in hematocrit, and polycythemia is sometimes seen (34).  High 
hematocrit is associated with increased CV risk in observational studies, and may contribute to events in 
men using testosterone (40).  A recent report suggested an association of venous thrombosis with 
testosterone therapy.  Glueck and coworkers identified 42 patients with thrombotic events a median of 
4.5 months after initiating testosterone therapy, 39 of whom were shown to have a hereditary 
thrombophilia (41).  The authors speculated that the events were attributable to estradiol formed by 
aromatization of the exogenous testosterone.  Estrogen therapy in women with hereditary 
thrombophilia markedly increases the risk of venous thrombosis (42).  However, estrogen levels in these 
women are higher than those in men using testosterone, and much of the risk with estrogen may be 
attributable to hepatic first pass effects of oral preparations, an effect which would not occur with 
testosterone therapy (43).  Nevertheless, men may be more sensitive to thrombotic effects of estradiol, 
and testosterone may have other actions that predispose men to thrombosis.  These observations 
require confirmation in a prospective trial.  There is also evidence that myocardial infarction is 
associated with hereditary thrombophilia, suggesting that if an association of testosterone with venous 
thrombosis is confirmed, testosterone  could increase the risk of arterial thrombosis as well (44).   
In spite of their limitations, the recent reports of CV events in older men on testosterone therapy raise 
significant concern that testosterone may be associated with adverse CV outcomes.  After publication of 
the Vigen and Finkle studies, the Endocrine Society issued a position statement recommending that 
testosterone only be prescribed in accordance with established guidelines, and only after discussion of 
possible CV risks with the patient (45).  The U.S. Food and Drug Administration recently required that all 
testosterone products include a general warning about venous thrombosis (46).  Until better data on the 
long term safety are available, a conservative approach to testosterone replacement in men with age 
and comorbidity-related declines in testosterone is warranted. 
What a cardiologist needs to know 
With many older men now using testosterone and extensive media coverage of potential CV risks, 
cardiologists will see patients with questions about the safety of testosterone (47).  Guidelines for 
testosterone therapy have been developed by several societies (12,48).  A full discussion of the 
considerations for initiation and monitoring of testosterone replacement is beyond the scope of this 
article.  There is considerable overlap of testosterone levels in hypogonadal men with those in 
asymptomatic, healthy men.  As a result, there is no consensus threshold for diagnosis of hypogonadism 
based on a laboratory value, and all guidelines emphasize the importance of interpreting a testosterone 
level in the context of the patient’s symptoms.  Due to intraindividual fluctuations, low testosterone 
levels should also be confirmed with a repeat morning measurement.  One guideline suggests that levels 
between 8 and 12 nmol/L (231 – 346 ng/dL) are borderline and require further investigation (48).  The 
Endocrine Society guideline simply notes that the lower limit of normal in young healthy men is usually 
9.7 to 10.4 nmol/L (280 – 300 ng/dL) (12).  There is significant variability among assays and it is 
recommended that practitioners consider the lower end of the normal range established by the 
laboratory they are using.  Given the high prevalence of conditions that alter SHBG in men with CV 
disease, it is our practice to base treatment decisions on calculated free testosterone rather than total 
testosterone.  The testosterone level should be monitored and the dose titrated to keep testosterone at 
or below the middle of the normal range for younger men.  Testosterone should be discontinued if there 
is no improvement in the symptoms being attributed to hypogonadism after a 4 to 6 month trial.  Until 
future studies clarify the CV risks of testosterone, it is also recommended that providers discuss possible 
vascular risks with patients considering testosterone replacement.   Specific contraindications to 
testosterone therapy include polycythemia, untreated obstructive sleep apnea, and poorly controlled 
heart failure, as testosterone may worsen these conditions (12).  Prostate cancer, unevaluated prostate 
nodules or prostate specific antigen elevations, severe lower urinary tract symptoms, and breast cancer 
are also contraindications.  Hematocrit, digital rectal exam, and prostate specific antigen should be 
monitored in men using testosterone.  Until better data on long term safety is available, cautious use of 
testosterone is recommended for older men and men with cardiovascular disease. 
Summary and future directions 
Millions of older men are now using testosterone for age related declines in serum testosterone and 
nonspecific symptoms.  The data on cardiovascular risks of testosterone in this population have 
significant limitations.  Observational studies have produced conflicting results and no prospective trial 
of testosterone therapy has examined CV events as a prespecified outcome.  There is no data on long 
term risks.  A few ongoing trials are examining the effect of testosterone replacement on markers of 
atherosclerosis progression (NCT00799617, NCT00287586, NCT00467987) or heart failure 
(NCT01813201, NCT01852994), but none of these studies are powered to assess differences in CV 
events.  In the absence of more definitive data, performing structured, consistent analyses of CV events 
in testosterone trials may facilitate firmer conclusions in a future meta-analysis (49).  Future trials 
should also include more biologically relevant free testosterone levels, not just total testosterone, and 
should always measure endogenous testosterone in the morning.  For patients with hypogonadism from 
diseases of the pituitary gonadal axis, testosterone cures their symptoms and improves quality of life.  
For men with age or chronic disease-related declines of testosterone, judicious use of testosterone 
therapy is preferred.  Given the conflicting findings of existing reports, additional retrospective studies 
are unlikely to resolve the controversy over testosterone therapy in older men.  A well designed, 
adequately powered, prospective trial of sufficient duration will ultimately be needed to determine if 
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Studies of Cardiovascular Events in Men on Testosterone Therapy 
 *The meta-analysis by Corona et al. identified 75 trials, but included only 26 in the main analysis.  The 
numbers in the table reflect trials included in the main analysis. 
Abbreviations:  ACS, acute coronary syndrome; CV, cardiovascular; HF, heart failure; HR, hazard ratio; 
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Vigen et al. 
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 Figure Legends 
 
Figure 1: Regulation of the pituitary-gonadal axis in adult men.  The pituitary is stimulated by 
gonadotropin releasing hormone (GnRH) from the hypothalamus to secrete leutenizing hormone (LH) 
and follicle stimulating hormone (FSH).  Leutenizing hormone stimulates testosterone synthesis in the 
Leydig cells of the testis, while FSH stimulates spermatogenesis.  Testosterone is converted in peripheral 
tissues to two other hormones, dihydrotestosterone (DHT) and estradiol.  Testosterone, DHT, and 
estradiol all feed back to the hypothalamus and pituitary to inhibit secretion of GnRH, LH, and FSH. 
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